Thiogenesis Therapeutics, Corp. announced a non brokered private placement to issue 6,000,000 common shares at ab issue price of CAD 0.75 per share for the gross proceeds of CAD 4,500,000 on November 20, 2023. The transaction is subject to the approval of the TSX Venture Exchange.

The Company anticipates closing of the Offering as soon as practicable subject to receipt of all necessary regulatory approvals. Upon issuance, the Offered Shares will be subject to a four-month and one day hold period pursuant to securities laws in Canada and, where applicable, Exchange policies. In connection with the Offering, the Company may pay finder's fees to eligible persons in compliance with applicable securities laws and Exchange policies.

The company will issue CAD 337,500 proceeds of securities pursuant to exemption provided under Regulation D. The transaction included participation from one non accredited investors.